Caribou Biosciences Inc. Common Stock (CRBU)

FairStock Score: 60/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Caribou as a Graham-style analyst: show me durable earnings first, then talk about science. This is a clinical-stage CRISPR genome-editing biopharmaceutical company with 97 employees, developing allogeneic cell therapies. Financially, it is not yet a business in the traditional sense. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $1.5 million and net loss was $24.3 million, or diluted EPS of -$0.24. For FY2025, revenue was $11.2 million and net loss was $148.1 million, or -$1.59 per diluted share. FY2024 and FY2023 also showed losses. FairStock's trailing free cash flow is -$95.8 million, which is a -190% FCF yield against the $50.4 million market cap at the 2026-10-13 close. That tells me cash burn is the central issue. The balance sheet shows debt/equity of 0.27, and the stock trades at a FairStock P/B of 0.51, which looks superficially cheap. But P/B can be misleading when losses consume book value. FairStock's Piotroski score is 2/9 and Altman Z-score is -5.40, both signaling weakness. Revenue growth of -43.79% and a latest-quarter net margin of -1619.88% do not demonstrate pricing power or a moat. The Lynch category is none because the company has lost money in each of the last four years. A low price is not the same as a margin of safety. Without profits, positive cash flow, or a proven commercial product, I can only call this a speculative clinical-stage venture, not a Graham bargain.

In plain English: Caribou Biosciences is a small medical research company that uses gene editing to try to develop cell therapies. It has no profits, brings in very little revenue, and is losing and spending much more money than it takes in. The stock price is very low, but the weak finances and heavy cash use make it hard to call cheap in a normal business sense.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer